- This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families.
- “CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer,” says QSAM CEO.
- Patent covers formulation and preparation of CycloSam in the U.S.
QSAM Biosciences (OTCQB: QSAM) has been awarded a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R). Granted by the U.S. Patent & Trademark Office, the patent “protects how CycloSam(R) is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs” (https://ibn.fm/J5Gvz).
“This patent issuance marks our third granted patent in the United States and further strengthens our IP estate, consisting of 14 patents among three distinct patent families,” stated QSAM Biosciences cofounder and CEO Douglas R. Baum. “Preparation and delivery of radiopharmaceuticals has historically been a challenge, but we believe the protection we have received for our kit formulation and preparation can provide a marketable advantage for both the manufacturing and supply chain for CycloSam, as well as potentially other drug candidates. We also believe CycloSam has potential to be a breakthrough therapy for both primary and secondary forms of bone cancer.”
QSAM, a company focused on developing next-generation targeted therapeutic radiopharmaceuticals for the treatment of cancer and related diseases, reported that the patent “covers both formulation and preparation of CycloSam in the U.S. with DOTMP kit formulations for radioisotope delivery targeting bone tumors, as well the high-dosage use of the radiopharmaceutical to perform bone marrow ablations.”
“The scope of this patent is fairly broad in that it not only protects the use of QSAM’s primary radioisotope, Samarium-153 (Sm-153), but also several other radioactive materials used in commercialized radiopharmaceuticals such as Lutetium-177 (Lu-177) and Yttrium-90 (Y-90) in conjunction with the chelating agent DOTMP,” the statement continues. “This patent provides the potential to add additional radiopharmaceuticals to QSAM’s pipeline. The kit itself is designed to provide convenient and reproducible preparation of the drug with better delivery and higher purity for each specific formulation.”
The patent is the latest of several noteworthy milestones for QSAM’s CycloSam. The targeted, bone-seeking therapeutic radiopharmaceutical has already shown preliminary safety and efficacy in animal studies as well as in a single-patient, FDA-cleared human trial performed in 2020. CycloSam uses low specific activity Samarium-153 combined with DOTMP, a chelator designed to reduce or eliminate off-target migration and targets sites of high bone turnover. The result is a potential treatment for primary and secondary bone cancers as well as a viable candidate for effectiveness trials in bone marrow ablation and procedures to reduce external beam radiation to bone tumors.
For more information, visit the company’s website at www.QSAMBio.com.
NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
